

# Budesonide Nasal Douching: An Effective Method in Postoperative AFRS Management

NEENA CHAUDHARY<sup>1</sup>, SHASHANK GUPTA<sup>2</sup>, RAJEEV KUMAR VERMA<sup>3</sup>, SANTOSHA RAM CHOUDHARY<sup>4</sup>

## ABSTRACT

**Introduction:** The aim of management of Allergic Fungal Rhinosinusitis (AFRS) is to control the disease process and the local immune response of the nasal mucosa. This is achieved by a two pronged approach – surgical clearance of all sinuses by Functional Endoscopic Sinus Surgery (FESS) followed by suppression of local immune response using steroids.

Recently delivery of topical steroid by way of douching has been introduced. The effect of budesonide in management of postoperative AFRS patients is yet to be studied.

**Aim:** To evaluate the role of budesonide nasal douching in postoperative management of AFRS.

**Materials and Methods:** A total of 60 postoperative AFRS patients were randomly divided into two groups. Both groups received routine post Functional Endoscopic Sinus Surgery (FESS) medication as per the institute protocol. One group of patients received budesonide douching in addition to the routine care. Both groups were evaluated endoscopically at

one, two and six weeks post op. Pre and postoperative quality of life change, patient complains, need for revision surgery and endoscopic Kupferberg scoring were used to compare the two postoperative groups.

**Results:** The average preoperative Sino-Nasal Outcome Test 22 (SNOT-22) score was 50.2. It was reduced to an average of 29.6 in patients who used the standard postoperative regimen and to 19.8 postoperatively in patients who had budesonide added to their douching solutions.

The average Kupferberg score was 1.2 for patients who did receive budesonide as compared to 1.9 for patients who did not receive budesonide douching.

**Conclusion:** Budesonide douching can offer a safe and effective tool in managing local inflammatory response in AFRS. It leads to a significantly better quality of life and has an effective response on nasal mucosa – leading to lesser mucosal oedema and lesser incidence of polypoidal changes postoperatively.

**Keywords:** Allergic fungal rhinosinusitis, Douching, Functional endoscopic sinus surgery

## INTRODUCTION

The discovery of AFRS can be traced back to 1971 when McCarthy and Pepys observed that 10% of patients with Allergic Broncho-Pulmonary Aspergillois (ABPA) also had symptoms of nasal obstruction due to plugs that were similar to the mucous plugs in their respiratory tract [1]. Culture of these plugs and samples of antral lavage grew *Aspergillus fumigatus*. Katzenstein et al., described the presence of “allergic mucin” in patients with Asthma, Nasal polyposis and Sinusitis [2]. They called the condition “allergic aspergillus sinusitis” and found that the allergic mucin contained laminated mucin, eosinophils, eosinophil Charcot-Leyden crystals, and fungal hyphae.

Since then a lot of research has been carried out in what is now called AFRS. Various diagnostic criteria have also been laid down for it. The most accepted criteria has been given by Bent III JP and Kuhn FA [Table/Fig-1] [3] and has been used in this study.

Effective control of the disease process relieves symptoms, improves quality of life and reduces recurrence of disease. Management includes a regimen of oral corticosteroids, topical steroid, nasal spray and hypertonic saline nasal douching.

Lately, there is increasing evidence that sprays and aerosols are not able to effectively reach the paranasal sinuses, and that, in most cases, these products do not even reach the middle meatus area.

In such a scenario, these low volume high pressure methods should be disregarded in favour of high-volume methods [4,5], with a daily irrigation of atleast 200 mL [6]. In view of evidence of better efficacy of high volume/low pressure solutions with respect to sinus penetration, nasal irrigation with corticosteroids have been used with encouraging results [7]. In this line, subgroups traditionally more difficult to control (e.g. Chronic Rhinosinusitis with polyps and increased tissue eosinophils) have better therapeutic response than the other subgroups [8].

Recently, delivery of topical steroid by way of douching has been introduced. One of the drugs used for instillation in topical forms is budesonide. Budesonide, at daily doses ranging from 250µg to 1 mg has been used [8]. Budesonide is a potent topical corticosteroid with an approximately 1,000-fold higher topical anti-inflammatory potency than cortisol. Budesonide binds the glucocorticoid receptor and exerts an anti-inflammatory effect through several mechanisms including altering the release of arachidonic acid metabolites, inhibiting the accumulation of leukocytes in a resected tissue, decreasing vascular permeability, inhibiting neuropeptide mediated responses, and altering the secretion of glycoproteins from sub-mucosal glands.

This study aims at evaluating the role of budesonide nasal douching as a tool for controlling local inflammation in post-FESS patients of AFRS.

## MATERIALS AND METHODS


This retrospective study was carried out at Department of ENT, VMMC & Safdarjung Hospital, New Delhi, India – a tertiary care hospital in north India between July 2014-December 2016. Ethical committee approval and fully informed patient consent were obtained.

A 60 post-FESS patients of AFRS [Table/Fig-2,3] who were operated for nasal polyposis were included in this study and were divided into cases and controls. They were included irrespective of their age and sex. Patients with comorbidities like diabetes mellitus, hypertension, or any other condition that prevented the use of standard postoperative protocol were not included in the study.

The standard treatment protocol at our center is to start the patient on oral Prednisolone 1 mg/kg one week prior to surgery which is then continued till one week post-op and then gradually tapered. Patients were also started on Fluticasone nasal spray and hypertonic saline nasal douching after nasal pack removal. Oral antibiotics are continued for one week postoperatively.

Major Criteria	Minor Criteria
Type 1 Hypersensitivity	Asthma
Nasal polyposis	Unilateral disease
Characteristic CT findings	Bone erosion
Eosinophilic mucin without invasion	Charcot-Leyden crystals
Positive Fungal Stain	Serum Eosinophilia
CT, Computed Tomography	Fungal culture positive

**[Table/Fig-1]:** Bent and Kuhn Criteria for diagnosis of AFRS [3].



**[Table/Fig-2]:** Nasal polyps with fungal debris and discharge. Patient diagnosed as suffering from AFRS. Right sided viewed with a 0-degree endoscope.


**[Table/Fig-3]:** Microscopic image showing "Charcot Leyden Crystals" (Black Arrow) – a minor criteria for diagnosing AFRS. H&E staining. 100X Magnification. (Images from left to right)

In addition to this regimen, we added budesonide nasal douching to the regimen of every alternate patient (i.e., 30 patients) that was operated. About 1 mg of budesonide was mixed in 500 mL normal saline and the solution was used for douching – half in the morning and half in the evening. Budesonide douching continued for a period of six weeks postoperatively. Since, budesonide was used in 1 mg/500 mL (0.002 mg/mL) concentration, same strength solution was used irrespective of age.

Patients were assessed endoscopically at one, six and 10 weeks postoperatively. SNOT-22 [Table/Fig-4] scoring was carried out during preoperative workup and at 10 weeks postoperative for both cases and controls. SNOT-22 is a subjective scoring form filled by the patient, describing their symptoms and their severity. It is a patient centered scoring method of evaluating how the patients perceive the symptoms and any relief or exaggeration experienced by them. Endoscopic evaluation of nasal mucosa was done using

	No Problem	Very Mild Problem	Mild or slight Problem	Moderate Problem	Severe Problem	Problem as bad as it can be	5 Most Important Items
1. Need to blow nose	0	1	2	3	4	5	-
2. Nasal Blockage	0	1	2	3	4	5	○
3. Sneezing	0	1	2	3	4	5	○
4. Runny nose	0	1	2	3	4	5	○
5. Cough	0	1	2	3	4	5	○
6. Post-nasal discharge	0	1	2	3	4	5	-
7. Thick nasal discharge	0	1	2	3	4	5	○
8. Ear fullness	0	1	2	3	4	5	○
9. Dizziness	0	1	2	3	4	5	○
10. Ear pain	0	1	2	3	4	5	○
11. Facial pain/pressure	0	1	2	3	4	5	-
12. Decreased Sense of Smell/Taste	0	1	2	3	4	5	○
13. Difficulty falling asleep	0	1	2	3	4	5	○
14. Wake up at night	0	1	2	3	4	5	○
15. Lack of a good night's sleep	0	1	2	3	4	5	○
16. Wake up tired	0	1	2	3	4	5	-
17. Fatigue	0	1	2	3	4	5	○
18. Reduced productivity	0	1	2	3	4	5	○
19. Reduced concentration	0	1	2	3	4	5	○
20. Frustrated/restless/irritable	0	1	2	3	4	5	○
21. Sad	0	1	2	3	4	5	-
22. Embarrassed	0	1	2	3	4	5	○

**[Table/Fig-4]:** SNOT-22 Questionnaire. "All rights reserved. Copyright 2006. Washington University in St. Louis, Missouri."



**[Table/Fig-5]:** Postoperative image of clear sinuses (with budesonide douching). Left side view with -degree endoscope showing maxillary and ethmoid sinuses.

**[Table/Fig-6]:** Postoperative image of clear maxillary and ethmoid sinus (without budesonide douching). Right sided view with zero degree endoscope showing ethmoid sinuses. (Images from left to right).

the Kupferberg [9] postoperative nasal mucosa endoscopic score [Table/Fig-5,6] at 10 weeks [Table/Fig-7]. Kupferberg scoring is an objective method of evaluating the status of the nasal mucosa. It is simple, accurate and reflects the status of the AFRS disease process.

Therefore, both subjective and objective criteria were used to compare the effects of budesonide nasal douching. The data was compared using student's t-test and Chi-square tests as applicable.

## RESULTS

The average age of the patients was 34.3 years with a male to female ratio of 1:1.6. The clinical features of all the patients are summarised in [Table/Fig-8].

The average preoperative SNOT-22 score was 50.2. It was reduced to an average of 29.6 in patients who used the standard postoperative regimen and to 19.8 postoperatively in patients who had budesonide added to their douching solutions. This difference was found to be statistically significant (p-value-0.02) [Table/Fig-9].

Two patients in the case group and two in the control group developed recurrence of disease and required revision surgery.

The average Kupferberg score was 1.2 for patients who received budesonide as compared to 1.9 for patients who did not receive budesonide douching. This difference was however not found to be statistically significant (p-value-0.10) [Table/Fig-10,11].

Grade	Endoscopic Findings
0	No mucosal oedema with no allergic mucin
1	Mucosal oedema with or without allergic mucin
2	Polypoidal oedema with or without allergic mucin
3	Sinus polyps with fungal debris/allergic mucin

**[Table/Fig-7]:** Kupferberg Postoperative Endoscopic Scoring [9].

Characterisitc	Number of patients (%)
Nasal Polyps	60 (100%)
Type 1 Hypersensitivity	42 (70%)
Characteristic CT findings	37 (61.7%)
Eosinophilic Mucin	28 (46.7%)
Positive Fungal Stain	11 (18.3%)
Asthma	32 (53.3%)
Unilateral disease (AFRS)	28 (46.7%)
Bone erosion present on CT scan	8 (13.3%)
Fungal culture positive	9 (15%)
Charcot-Leyden crystals	16 (26.7%)
Serum Eosinophilia	25 (41.7%)

**[Table/Fig-8]:** Clinical features of all patients in the study.

	SNOT-22 Score
Preoperative	50.2
Postop Without budesonide	29.6
Postop With budesonide	19.8

**[Table/Fig-9]:** SNOT-Scores.

	Average Kupferberg Scores
Postop without budesonide	1.9
Postop with budesonide	1.2

**[Table/Fig-10]:** Kupferberg Scores.

Kupferberg Scores	Post-op without Budesonide	Post-op with Budesonide
0	2	8
1	7	11
2	13	8
3	8	3

**[Table/Fig-11]:** Postoperative Kupferberg scores of patients who received budesonide and those who didn't.

## DISCUSSION

The safety and usefulness of this method of delivering topical steroids has been studied in CRS and been accepted by many physicians [8,11-13]. Various authors have used budesonide solutions of different strengths to good effect in managing Chronic Rhinosinusitis. Seiberling et al., used 0.25 mg budesonide per day [14], Welch et al., used 2 mg/day while Bhalla used 1 mg/day for nasal douching by mixing respules of budesonide in normal saline [10,15]. All authors have achieved varying degrees of success using topical steroid douching in controlling nasal mucosa inflammation.

In our knowledge, this is the first study aimed at evaluating the role of topical budesonide therapy in managing postoperative AFRS cases. Our study shows that budesonide douching can offer a safe

and effective tool in managing local inflammatory response in AFRS. It leads to a significantly better quality of life and has an effective response on nasal mucosa – leading to lesser mucosal oedema and lesser incidence of polypoidal changes postoperatively.

## LIMITATION

This study has certain limitations. A larger sample size is required before definitive recommendations can be made. Also, a longer follow-up period is required to completely evaluate the efficacy of budesonide douching.

## CONCLUSION

On the basis of our findings, we recommend that budesonide nasal douching is an effective and useful adjunctive therapy in postoperative management of AFRS patients. It provides a better quality of life and is helpful in controlling the disease progression.

Future larger controlled trials are needed to improve the level of evidence for effectiveness and to assess the safety of higher doses and longer-term therapy of budesonide irrigations in patients with AFRS.

## REFERENCES

- [1] McCarthy DS, Pepys J. Allergic broncho-pulmonary aspergillosis. *Clin Allergy*. 1971;1:261-86.
- [2] Katzenstein AL, Sale SR, Greenberger PA. Allergic Aspergillus Sinusitis A newly recognized form of sinusitis. *J Allergy Clin Immunol*. 1983;72(1):82-93.
- [3] Bent III JP, Kuhn FA. Diagnosis of allergic fungal sinusitis. *Otolaryngology, Head and Neck Surgery*. 1994;111(5):580-88.
- [4] Wormald PJ, Cain T, Oates L, Hawke L, Wong I. A comparative study of three methods of nasal irrigation. *Laryngoscope*. 2004;114(12):2224-27.
- [5] Abadie WM, McMains KC, Weitzel EK. Irrigation penetration of nasal delivery systems: a cadaver study. *Int Forum Allergy Rhinol*. 2011;1(1):46-49.
- [6] Rudmik L, Hoy M, Schlosser RJ, Harvey RJ, Welch KC, Lund V, et al. Topical therapies in the management of chronic rhinosinusitis - an evidence-based review with recommendations. *Int Forum Allergy Rhinol*. 2013;3(4):281-98.
- [7] Steinke JW, Payne SC, Tessier ME, Borish LO, Han JK, Borish LC. Pilot study of budesonide inhalant suspension irrigations for chronic eosinophilic sinusitis. *J Allergy Clin Immunol*. 2009;124(6):1352-54.e7.
- [8] Snidvongs K, Pratt E, Chin D, Sacks R, Earls P, Harvey RJ. Corticosteroid nasal irrigations after endoscopic sinus surgery in the management of chronic rhinosinusitis. *Int Forum Allergy Rhinol*. 2012;2(5):415-21.
- [9] Kupferberg SB, Bent JP, Kuhn FA. Prognosis for allergic fungal sinusitis. *Otolaryngol Head Neck Surg*. 1997;117(1):35-41. PubMed PMID: 9230320.
- [10] Welch KC, Thaler ER, Doghramji LL, Palmer JN, Chiu AG. The effects of serum and urinary cortisol levels of topical intranasal irrigations with budesonide added to saline in patients with recurrent polyposis after endoscopic sinus surgery. *Am J Rhinol Allergy*. 2010;24(1):26-28.
- [11] Sachanandani NS, Piccirillo JF, Krampfer MA, Thawley SE, Vlahiotis A. The effect of nasally administered budesonide respules on adrenal cortex function in patients with chronic rhinosinusitis. *Arch Otolaryngol Head Neck Surg*. 2009;135(3): 303-07.
- [12] Thamboo A, Manji J, Szeitz A, Santos RD, Hathorn I, Gan EC, et al. The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal polyposis. *Int Forum Allergy Rhinol*. 2014;4(5):397-402.
- [13] Jang DW, Lachanas VA, Segel J, Kountakis SE. Budesonide nasal irrigations in the postoperative management of chronic rhinosinusitis. *Int Forum Allergy Rhinol*. 2013;3(9):708-11.
- [14] Seiberling KA, Chang DF, Nyirady J, Park F, Church CA. Effect of intranasal budesonide irrigations on intraocular pressure. *Int Forum Allergy Rhinol*. 2013;3(9):704-07.
- [15] Bhalla RK, Payton K, Wright ED. Safety of budesonide in saline sinonasal irrigations in the management of chronic rhinosinusitis with polyposis: lack of significant adrenal suppression. *J Otolaryngol Head Neck Surg*. 2008;37(6): 821-25.

### PARTICULARS OF CONTRIBUTORS:

1. Professor, Department of Otorhinolaryngology, VMMC and Safdarjung Hospital, Delhi, India.
2. Junior Resident, Department of Otorhinolaryngology, VMMC and Safdarjung Hospital, Delhi, India.
3. Senior Resident, Department of Otorhinolaryngology, VMMC and Safdarjung Hospital, Delhi, India.
4. Senior Resident, Department of Otorhinolaryngology, VMMC and Safdarjung Hospital, Delhi, India.

### NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Rajeev Kumar Verma,  
Krashi Upaz Mandi Road, Ward No 1, Shrimadhapur, Siker-332715, Rajasthan, India.  
E-mail: drrajeevkumar85@gmail.com

**FINANCIAL OR OTHER COMPETING INTERESTS:** None.

Date of Submission: **Mar 16, 2017**  
Date of Peer Review: **May 05, 2017**  
Date of Acceptance: **Aug 01, 2017**  
Date of Publishing: **Dec 01, 2017**